Specialty Rx Coverage Should Focus On Appropriate Use, Not Cost Sharing
Executive Summary
Focusing on methods to ensure appropriate use may be more effective in controlling spending on specialty pharmaceuticals than prior authorization and cost sharing strategies, a series of articles in the September/October issue of Health Affairs suggest
You may also be interested in...
Consumers Are Willing To Pay More For Specialty Meds, Express Scripts Finds
An Express Scripts analysis found that consumers are potentially willing to pay more for specialty drugs
Tysabri Out Of Remission; Returns With Updated Indication, Risk Management
The indication for Biogen Idec/Elan's re-approved multiple sclerosis therapy Tysabri (natalizumab) stops short of limiting it to use as a second-line therapy
India Highlights "Public Interest" To Reign In Prices For Non-Scheduled Drugs
Dr. Reddy's, GSK, Ranbaxy and UCB among manufacturers that could see prices reduced under government order that reflects issues raised in Gleevec patent dispute.